SmithKline

Abbott, Astellas collaborate on CMV vaccine trial

Monday, September 10, 2012 11:03 AM

Abbott has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for ASP0113 (TransVax), an investigational vaccine licensed from Vical for preventing cytomegalovirus (CMV) reactivation in transplant patients.

More... »

Genentech and Novartis rank as image leaders among oncologists, hematologists

Wednesday, July 25, 2012 09:59 AM

Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study.

More... »

GSK to acquire Human Genome Sciences for $14.25 per share in cash

Monday, July 16, 2012 10:51 AM

GlaxoSmithKline and Human Genome Sciences have announced a definitive agreement under which GSK will acquire HGS for $14.25 per share in cash.

More... »

GSK, Theravance report positive results from four phase III COPD studies

Monday, July 2, 2012 03:09 PM

GlaxoSmithKline and Theravance, a biopharmaceutical company based in San Francisco, issued results from four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease (COPD).

More... »

GSK further extends HGS tender offer

Friday, June 29, 2012 02:14 PM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on July 20, 2012.

More... »

GSK receives FDA approval for MenHibrix

Monday, June 18, 2012 12:33 PM

The FDA has approved GlaxoSmithKline’s vaccine MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b in children aged six weeks through 18 months.

More... »

HGS sets July 16 deadline for acquisition proposals

Friday, June 15, 2012 02:09 PM

In connection with its ongoing strategic alternative review process, Human Genome Sciences (HGS) has set a bid date of July 16, 2012, for the submission of definitive proposals to acquire all outstanding common shares of HGS.

More... »

GSK extends tender offer for HGS shares

Monday, June 11, 2012 09:49 AM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on Friday, June 29, 2012. The tender offer was previously scheduled to expire at 12:00 midnight EST, at the end of the day on June 7, 2012.

More... »

GSK’s Hart-Scott-Rodino waiting period expires for HGS tender offer

Monday, June 4, 2012 10:55 AM

GlaxoSmithKline’s waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, expired as of June 1, 2012, giving GSK clearance to acquire all outstanding shares of Human Genome Sciences.

More... »

Two GSK melanoma drugs garner top results

Monday, June 4, 2012 10:21 AM

GlaxoSmithKline released results from two of its phase III melanoma studies: one evaluating single agent therapy with the targeted anti-cancer agents, dabrafenib and trametinib, in patients with BRAF V600 mutation positive metastatic melanoma; and one evaluating trametinib alone.

More... »